Our Platform 

Our proprietary autologous fibroblast technology is the foundation for creating personalized biologics for diseases of the skin and connective tissue.

The Science of Autologous Fibroblasts

Fibroblasts are the basis of Fibrocell’s personalized cell and gene therapy platform because they are the most common cell in skin and connective tissue and are responsible for synthesizing extracellular matrix proteins, including collagen, that provide structure and support.

science of autologous fibroblasts

Fibroblasts—the most common cells in the body—provide an ideal foundation for Fibrocell’s personalized biologics:



Fibroblasts are present in all skin and connective tissue.

Readily Sourced from Skin

Fibroblasts can be isolated from the skin and grown in culture. The ability to genetically modify fibroblasts has been well documented in scientific literature.

Functionally Critical

Fibroblasts synthesize the structural framework of tissue.

Ideal Delivery Vehicle

Fibroblasts have unique capabilities for localized (vs. systemic) delivery to gene targets in the skin and connective tissue.

Our entire fibroblast platform is done autologously. This approach allows us to avoid many of the rejection concerns presented with allogeneic cells and results in a higher likelihood of efficacy.”

— John Maslowski, President and Chief Executive Officer

Personalized Biologics Approach

Fibrocell’s autologous fibroblast technology uses our patented manufacturing process, which involves collecting small skin biopsies from patients, isolating cells and expanding them in culture, transducing the fibroblast cells with an integrative lentiviral vector to express a targeted protein, followed by continued expansion of the gene-modified cells in culture. In this manner, each patient is treated with cells that were cultivated from his or her own dermal tissue (i.e., autologous). 

Fibrocell-personalized-biologics-approach (1)